SWOT ANALYSIS INFORMATION

2

The company

Our priority as a pharmaceutical firm is the development of new and improved treatments

for patients. We are called 4LIFE Pharmaceuticals, and our headquarters are in Boston. Our

group includes researchers, scientists, and professionals from many different backgrounds, all

with a common goal of making medical progress. We are fast growing and now employ roughly

500 individuals. Our firm's tagline is "Innovative therapies for a better tomorrow." This

exemplifies our determination to explore new avenues of research and produce cutting-edge

therapies to meet urgent medical needs. Our cutting-edge strategy in medication research is a

vital part of our mission to provide health and happiness to people all around the globe. Our

mission is to improve people's lives around the world by giving them access to innovative, cost-

effective treatments.

Introduction to the Innovation

Article A's scientific methodology as follows:

Observation: Mutations in the beta-globin gene produce beta-thalassemia, characterized

by anemia (Khosravi et al., 2019). Anemia and organ failure are only two of the many potentially

fatal symptoms brought on by this disease. Therapy for beta-thalassemia may include stimulating

the synthesis of fetal hemoglobin (HbF) to make up for the hemoglobin deficiency in adults.

Question: Can HbF restoration be achieved using CRISPR-Cas9-mediated targeted

removal of the BCL11A gene, a critical regulator of HbF production? This strategy holds great

promise for the gene treatment of beta-thalassemia. Hypothesis: Reactivating HbF in human

erythroid cells after selective eradication of the BCL11A gene using the CRISPR-Cas9

technology offers hope for treating beta-thalassemia. Experiment: Human erythroid cells were

treated using CRISPR-Cas9 method to eliminate the BCL11A gene, and HbF generation was

3

then assessed. They determined HbF and adult hemoglobin concentrations using HPLC and

qPCR, and Sanger sequencing verified the system's selectivity. Results: Employing the CRISPR-

Cas9 method, researchers were able to selectively eliminate the BCL11A gene in human

erythroid cells, resulting in a dramatic revival of HbF activity with no discernible impact on adult

hemoglobin output (Khosravi et al., 2019). The CRISPR-Cas9 method was effective and

selective, with no evidence of off-target consequences. Conclusion: This research demonstrates

that HbF revival in human erythroid cells may be achieved by directed elimination of the

BCL11A gene utilizing the CRISPR-Cas9 system, suggesting that this may be a viable strategy

beta-thalassemia gene therapy. Conclusion: This research demonstrates that HbF revival in

human erythroid cells may be achieved by directed elimination of the BCL11A gene utilizing the

CRISPR-Cas9 system, suggesting that this may be a viable strategy beta-thalassemia gene

therapy.

The Eureka moment for primary article A was the impressive effectiveness and specificity

in eliminating the BCL11A gene from human erythroid cells, resulting in significant HbF

reactivation without compromising adult hemoglobin synthesis, really jumped out to me. This

study has exciting implications for the development of gene therapy to treat beta-thalassemia, a

genetic illness affecting millions of individuals throughout the globe. Using the above-described

Eureka moment as inspiration, I have developed a novel approach to gene therapy for beta-

thalassemia by focusing on the hematopoietic stem cells (HSCs) to locate and remove the

BCL11A gene. By exchanging faulty HSCs with genetically engineered HSCs that can generate

typical quantities of HbF and adult hemoglobin, this strategy promises to offer a permanent

treatment for beta-thalassemia.

Futuring Techniques

4

Opportunity and risk may be better assessed for an industry, company, or society by

making a futuring study, a methodical and deliberate approach for examining possible future

scenarios and trends (Rasmussen & Foss, 2015). A futuring study aims to look forward to

potential outcomes so that present-day choices may be well-informed. To spot patterns and come

up with original approaches, futurists use various tools and methodologies.

Describing Two Futuring Analysis Techniques

Scenario planning and trend analysis are the two futuring methods of analysis that are

most applicable to my novel concept. Analyzing past data and ongoing trends to make

predictions about the future is called trend analysis. It operates on the premise that existing

patterns may be used to predict future developments. Consumer surveys and professional

journals are just some data sources that may be used in a trend analysis (Yang et al., 2018).

Changes in customer tastes, new technology, and fluctuations in consumer demand are just a few

examples of the patterns and developments that may be uncovered by analyzing the collected

data (Kim & Delen, 2018).

By using economic, social, political, technical, and ecological trends, scenario planning

generates realistic and alternate scenarios of potential future events (Culot et al., 2020). It is

predicated on the idea that there is no way to know what will happen in the future and that a wide

range of possible outcomes exists. Stakeholders, trend analysis, and experts are excellent options

for looking for valuable data and information during scenario planning.

Significance of Each Technique

Services and goods in the biological sciences will continue to be influenced by

developing technology and market conditions, making trend analysis an essential tool for

predicting the future development of these sectors (Yang et al., 2018). Genomic analysis, tailored

5

treatment, and AI research may help businesses foresee the future to adapt their plans

accordingly (Kim & Delen, 2018). Businesses may create novel gene treatments for curing

genetic illnesses like thalassemia by monitoring developments in gene editing tech.

Scenario planning is vital for the life sciences industry because it allows businesses to plan for

various possible futures for their goods and services (Cuhls, 2020). Companies may anticipate

potential possibilities and risks in various future contexts by building a set of possible scenarios.

Corporations might foresee the effects of potential changes in payment methods by analyzing

scenarios connected to healthcare policy shifts. Scenario planning may help businesses prepare

for unidentified dangers.

Futuring Techniques Applied

Two futuring methods that might be used for the novel notion of employing CRISPR-

Cas9 technology to reactivate fetal hemoglobin as a therapy for beta-thalassemia are trend

analysis and scenario planning. Scenario planning is a technique used in strategic planning to

explore and create possible future outcomes to help discover opportunities and risks (Cuhls,

2020). It may be used to analyze and predict how it can be further developed and used in the

fight against beta-thalassemia. The goal of trend analysis is to examine data from the past to

draw conclusions about the future (Yang et al., 2018). Application of this method to the

innovation will reveal patterns in the growth of gene treatments for beta-thalassemia and the

regulatory climate for CRISPR-Cas9 applications.

Table 1: Futuring Techniques Applied

First Technique

Scenario Planning

Second Technique

Trend Analysis

6

Futuring

Technique

Results

(3 results for

each)

Scenario 1: CRISPR-Cas9

technology to reactivate fetal

hemoglobin is now the accepted

norm for treating beta-thalassemia in

high-income nations.

Scenario 2: CRISPR-Cas9

treatment for beta-thalassemia has

been slow to catch on in certain

parts of the world due to ethical and

legal obstacles around the

application of gene editing

technologies.

Scenario 3: CRISPR-Cas9 and other

gene editing advances pave the way

for more precise and effective

treatments for beta-thalassemia.

Trend 1: Beta-thalassemia is

becoming more common, which

might increase the need for gene

therapy.

Trend 2: CRISPR-Cas9 treatment

might take longer to complete

because of increased scrutiny from

regulators concerned about ensuring

the therapy's effectiveness and safety.

Trend 3: Better therapies for beta-

thalassemia may be created with the

help of new technology and methods.

Conclusion

Both methods of foresight led me to the conclusion that developing my possible

invention would be a good use of one's time and money. Possible future trends, difficulties, and

possibilities for development and accomplishment in the life sciences business have been

illuminated using scenario planning and trend analysis. These findings suggest that the market

may embrace my idea well and help meet current and future demands. The futuring study

7

indicates that my concept has an excellent chance for triumph and deserves to be explored,

despite the dangers and uncertainties inherent in any new breakthrough.

References

Cuhls, K. E. (2020). Horizon Scanning in Foresight–Why Horizon Scanning is only a part of the

game. Futures & Foresight Science, 2(1), e23. https://doi.org/10.1002/ffo2.23

Culot, G., Orzes, G., Sartor, M., & Nassimbeni, G. (2020). The future of manufacturing: A

Delphi-based scenario analysis on Industry 4.0. Technological forecasting and social

change, 157, 120092. https://doi.org/10.1016/j.techfore.2020.120092

Khosravi, M. A., Abbasalipour, M., Concordet, J. P., Vom Berg, J., Zeinali, S., Arashkia, A., ... &

Karimipoor, M. (2019). Targeted deletion of BCL11A gene by CRISPR-Cas9 system for

fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia

disease. European Journal of Pharmacology, 854, 398–405.

https://doi.org/10.1016/j.ejphar.2019.04.042

Kim, Y. M., & Delen, D. (2018). Medical informatics research trend analysis: A text mining

approach. Health informatics journal, 24(4), 432-452.

https://doi.org/10.1177/1460458216678443

Rasmussen, K., & Foss, N. (2015). Business Model Innovation in the Pharmaceutical Industry.

Business Model Innovation, 240–268.

https://doi.org/10.1093/acprof:oso/9780198701873.003.0012

Yang, C., Huang, C., & Su, J. (2018). An improved SAO network-based method for technology

trend analysis: A case study of graphene. Journal of Informetrics, 12(1), 271-286.

https://doi.org/10.1016/j.joi.2018.01.006